Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Et tverrfaglig vekttapsprogram ved AUB-MC

3. november 2026 oppdatert av: Marlene Chakhtoura, American University of Beirut Medical Center

Et tverrfaglig vekttapsprogram ved AUB-MC: An Open Label Pilot Randomized Controlled Trial

The current project aims at evaluating the feasibility and efficacy of a multi-disciplinary weight loss program, using an innovative and simple dietary intervention at the American University of Beirut Medical Center (AUB-MC). Such intervention is expected to enhance patients' compliance and adherence to lifestyle changes. In addition, the program includes supervised exercise sessions and behavioral therapy. Therefore, our project proposes an evidence based approach to close the obesity treatment gaps.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

20

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Riad El Solh
      • Beirut, Riad El Solh, Libanon, 1107 2020
        • American University of Beirut - Medical Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Lebanese adult with obesity (≥18 years), obesity being defined as BMI ≥ 30 kg/m2
  • Patients who can commit to frequent visit trials as per study protocol
  • Patients not traveling outside Lebanon for at least the 6-month period of the trial
  • Patients tolerating Metformin after a run-in period of 2 weeks

Exclusion Criteria:

  • Patients who have taken other weight reducing drug therapy in the previous 6 months
  • Patients who have undergone bariatric therapy or endoscopic procedure, or planning to do so in the near future (at < 6 months)
  • Patients with diabetes
  • Patients working at AUB-MC, as we will not be able to assess the adherence to study visits nor the feasibility of such a program in the general population, presenting to AUB-MC only for clinical care
  • A family member of a patient already enrolled in the study, as the participants will not be independent
  • Pregnant obese patients
  • Patients with pacemakers
  • Patients known to have hypertension, cardiac, pulmonary, renal or liver disease, active cancer or psychiatric illnesses
  • History of any surgery of less than 6 weeks duration
  • Patients known to have disabling osteoarthritic or orthopedic problems
  • Patients secondary uncontrolled endocrine disorders (thyroid disorders, polycystic ovary, Cushing disease), or drug induced obesity (such as anti-psychotic, steroids, hormonal therapy).

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Multidisciplinary program

Multidisciplinary weight loss program

Diet and behavioral therapy,and supervised exercise sessions

1 tablet, twice daily

Annen: Control

Standard care

1 tablet, twice daily

General lifestyle tips

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Mean percent weight loss per treatment arm
Tidsramme: 6 months after enrollment

[(baseline weight-follow up weight at 6 months)/ baseline weight] X 100

6 months after enrollment

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in weight
Tidsramme: 6 months after enrollment

TANITA Body Composition (BC) 418 MA Segmental Body Composition Analyzer will measure Weight in kg

6 months after enrollment
Change in BMI
Tidsramme: 6 months after enrollment

TANITA BC 418 MA Segmental Body Composition Analyzer will measure BMI (kg/m^2) by combining the height and weight.

6 months after enrollment
Change in body composition
Tidsramme: 6 months after enrollment

TANITA BC 418 MA Segmental Body Composition Analyzer will measure total body measurements for: Fat Mass, Fat Free Mass, Total Body Water (in kg)

6 months after enrollment
basal metabolic rate (BMR)
Tidsramme: 6 months after enrollment

TANITA BC 418 MA Segmental Body Composition Analyzer will measure BMR

6 months after enrollment
Change in physical fitness (distance)
Tidsramme: 6 months after enrollment

Physical fitness will be assessed using the 6 minute walk test. Measure to be collected at beginning and end of test is: distance covered in meters

6 months after enrollment
Change in resting blood pressure before and after physical exercise
Tidsramme: 6 months after enrollment

Physical fitness will be assessed using the 6 minute walk test. Measure to be collected at beginning and end of test is: resting blood pressure

6 months after enrollment
Change in oxygen saturation before and after physical exercise
Tidsramme: 6 months after enrollment

Physical fitness will be assessed using the 6 minute walk test. Measure to be collected at beginning and end of test is: oxygen saturation

6 months after enrollment
Change in heart rate before and after physical exercise
Tidsramme: 6 months after enrollment

Physical fitness will be assessed using the 6 minute walk test. Measure to be collected at beginning and end of test is: heart rate.

6 months after enrollment
Change in physical fitness (Perceived Exertion)
Tidsramme: 6 months after enrollment

Physical fitness will be assessed using the 6 minute walk test. Rated Perceived Exertion (RPE) scale score will be administered.

6 months after enrollment
Change in levels of appetite hormones and metabolic markers
Tidsramme: 6 months after enrollment

At visit 3 and completion visit (visit 5), blood samples will be withdrawn for various hormones and proteins related to appetite and satiety including Gastric inhibitory polypeptide (GIP), Leptin, Glucagon like peptide 1 (GLP1), Irisin, Insulin, Ghrelin, Orexin, IL6

These samples will be processed and preserved in the Calcium Metabolism and Osteoporosis Program lab in our institution, and the tests will be run later on, when additional funds are available.

6 months after enrollment
Change in levels of Mineral markers and hormones (cross laps)
Tidsramme: 6 months after enrollment

At visit 3 and completion visit (visit 5), blood samples will be withdrawn for various mineral markers and hormones including Crosslaps (pg/mL).

These samples will be processed and preserved in the Calcium Metabolism and Osteoporosis Program lab in our institution, and the tests will be run later on, when additional funds are available.

6 months after enrollment
Change in levels of Mineral markers and hormones (Osteocalcin)
Tidsramme: 6 months after enrollment

At visit 3 and completion visit (visit 5), blood samples will be withdrawn for various mineral markers and hormones including Osteocalcin (ng/mL).

These samples will be processed and preserved in the Calcium Metabolism and Osteoporosis Program lab in our institution, and the tests will be run later on, when additional funds are available.

6 months after enrollment
Participants' compliance
Tidsramme: 6 months after enrollment

Adherence to the dietary intervention: [Number of days the dieticians are contacted/ Total number of days] X 100 Adherence to program visits: [Number of visits attended/ Total number of visits] X 100

6 months after enrollment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

15. august 2023

Primær fullføring (Antatt)

15. september 2027

Studiet fullført (Antatt)

15. september 2027

Datoer for studieregistrering

Først innsendt

18. juli 2019

Først innsendt som oppfylte QC-kriteriene

10. desember 2019

Først lagt ut (Faktiske)

11. desember 2019

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere